1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > US Companion Diagnostics Market Trends and Insights

US Companion Diagnostics Market Trends and Insights

  • April 2014
  • -
  • Frost & Sullivan
  • -
  • 121 pages

A complete companion diagnostic market analysis must include both developers of targeted drugs and developers of companion diagnostic tests. This research deliverable discusses important trends in the U.S. companion diagnostics market including emerging opportunities with novel drug classes and new clinical markers like circulating tumor cells. Emerging therapeutic areas beyond oncology for companion diagnostics are also discussed along with key competitors, rx-cdx partnerships, regulatory overview, and therapeutic pipelines with companion biomarkers.


Key Findings

There were at least 387 targeted medicines in the pipeline or currently marketed for oncology in 2013. breast cancer, non-small cell lung cancer (NSCLC), and colorectal cancer have the most targeted drug development activity.

Novartis and Roche lead with the most targeted therapies currently marketed and in development. AstraZeneca, GSK, Pfizer, Sanofi, and BMS are also focused on targeted therapies marketed with or likely requiring a companion diagnostics (CDx).

Key market drivers include the unmet need for Cdx in highly mutationally driven cancers such as NSCLC and melanoma and the growing interest in novel clinical epigenetic biomarkers and circulating tumor cells.

A promising new drug class, the antibody drug conjugate (ADC), may provide new opportunities for CDx. Roche, ImmunoGen, and Seattle Genetics all have a high number of ADCs in the pipeline and may be attractive targets for CDx partnering.

Advances such as highly sensitive microfluidic biosensors, single cell analysis, and deep sequencing of circulating cell-free tumor DNA are making the concept of the liquid biopsy, or the ability to monitor a tumor noninvasively, a near-term reality.

Oncology is the primary therapeutic area for CDx development, but neurological, cardiovascular, gastrointestinal, and muscular diseases are growing areas for CDx. Within oncology, lung cancer was the most prominent area where most partnerships between manufacturers were observed.

Most CDx partnerships were defined over the regions of the United States and Europe, the two most important CDx markets.

Table Of Contents

US Companion Diagnostics Market Trends and Insights
Table of Contents


Executive Summary 4
Market Overview and Trends 6
Product Analysis: BRAF, EGFR, KRAS 12
Companion Biomarker Opportunities in Drug Development 21
Competitive Playbook 25
US Regulatory Overview 37
Appendix 43
Therapeutic Pipeline with Companion Biomarker—By Pharmaceutical Company 48
Therapeutic Pipeline with Companion Biomarker—By Cancer Type 54
The Frost and Sullivan Story 114

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • November 2016
    15 pages
  • Cancer  

  • United Kingdom  

View report >

Related Market Segments :

Lung Cancer
Oncology
Biomarker

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.